

# Alessandra Mangia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3640894/publications.pdf>

Version: 2024-02-01

265  
papers

18,212  
citations

26567

56  
h-index

12910

131  
g-index

279  
all docs

279  
docs citations

279  
times ranked

13021  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.   | 13.9 | 2,352     |
| 2  | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.   | 13.9 | 1,605     |
| 3  | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.  | 13.9 | 1,580     |
| 4  | Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.   | 13.9 | 945       |
| 5  | Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.   | 13.9 | 752       |
| 6  | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.   | 13.9 | 740       |
| 7  | Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. <i>New England Journal of Medicine</i> , 2005, 352, 2609-2617.  | 13.9 | 672       |
| 8  | Sustained virological response to interferon- $\alpha$ is associated with improved outcome in HCV-related cirrhosis: A retrospective study. <i>Hepatology</i> , 2007, 45, 579-587.                | 3.6  | 585       |
| 9  | Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2006, 130, 1636-1642.                    | 0.6  | 517       |
| 10 | An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. <i>Gastroenterology</i> , 2010, 139, 821-827.e1. | 0.6  | 285       |
| 11 | A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.   | 13.9 | 284       |
| 12 | Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.     | 3.6  | 232       |
| 13 | Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. <i>Hepatology</i> , 2008, 47, 43-50.  | 3.6  | 225       |
| 14 | The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. <i>Hepatology</i> , 2007, 45, 1164-1171.               | 3.6  | 214       |
| 15 | Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2000, 51, 1-7.   | 0.5  | 199       |
| 16 | Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.   | 0.4  | 197       |
| 17 | NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , 2017, 66, 910-918.             | 1.8  | 192       |
| 18 | Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235.                          | 2.0  | 187       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013, 58, 65-72.   | 3.6 | 159       |
| 20 | Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.  | 5.8 | 156       |
| 21 | An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. <i>Journal of Hepatology</i> , 2005, 42, 744-751.   | 1.8 | 155       |
| 22 | SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.  | 3.6 | 151       |
| 23 | Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3729-3734.                | 1.8 | 146       |
| 24 | Noninvasive Diagnosis of NAFLD and NASH. <i>Cells</i> , 2020, 9, 1005.  | 1.8 | 145       |
| 25 | Hepatitis C pharmacogenetics: State of the art in 2010. <i>Hepatology</i> , 2011, 53, 336-345.  | 3.6 | 131       |
| 26 | TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. <i>Gastroenterology</i> , 2018, 154, 1764-1777.e7.                 | 0.6 | 123       |
| 27 | HCV and diabetes mellitus: evidence for a negative association. <i>American Journal of Gastroenterology</i> , 1998, 93, 2363-2367.  | 0.2 | 118       |
| 28 | Reduced IFNÎ»4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.  | 5.8 | 117       |
| 29 | HLA class II favors clearance of HCV infection and progression of the chronic liver damage. <i>Journal of Hepatology</i> , 1999, 30, 984-989.   | 1.8 | 113       |
| 30 | The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216. | 1.9 | 111       |
| 31 | Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 397-404.  | 1.9 | 104       |
| 32 | MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.  | 5.8 | 104       |
| 33 | Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.   | 0.6 | 99        |
| 34 | High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050.                                | 3.6 | 92        |
| 35 | IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. <i>Cytokine</i> , 2004, 25, 103-109.   | 1.4 | 90        |
| 36 | International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.   | 2.5 | 87        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.  | 2.5 | 87        |
| 38 | IFN- $\gamma$ 3, not IFN- $\gamma$ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.   | 9.4 | 86        |
| 39 | Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.   | 1.9 | 84        |
| 40 | Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.  | 3.6 | 83        |
| 41 | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.                        | 3.6 | 82        |
| 42 | Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 745-751.  | 0.8 | 81        |
| 43 | Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1479-1481.    | 2.9 | 81        |
| 44 | Anticardiolipin Antibodies in Patients With Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 2983-2987.  | 0.2 | 78        |
| 45 | The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.   | 3.6 | 74        |
| 46 | Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.  | 1.8 | 73        |
| 47 | Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6. | 2.4 | 72        |
| 48 | Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.                               | 3.6 | 67        |
| 49 | Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.  | 3.6 | 67        |
| 50 | Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016, 63, 1112-1119.  | 3.6 | 67        |
| 51 | Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.  | 1.9 | 66        |
| 52 | Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2009, 49, 358-363.  | 3.6 | 64        |
| 53 | FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.  | 1.8 | 64        |
| 54 | Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- $\alpha$ in Huh-7 cells. <i>Journal of General Virology</i> , 2010, 91, 1678-1686.  | 1.3 | 58        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011, 54, 789-800.   | 3.6 | 58        |
| 56 | Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. <i>Antiviral Therapy</i> , 2018, 23, 229-238.  | 0.6 | 57        |
| 57 | Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.   | 0.4 | 56        |
| 58 | Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. <i>Hepatology</i> , 2011, 54, 772-780.  | 3.6 | 56        |
| 59 | O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. <i>Journal of Hepatology</i> , 2015, 62, S221.  | 1.8 | 56        |
| 60 | Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048. | 2.9 | 56        |
| 61 | Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.   | 2.2 | 55        |
| 62 | Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. <i>PLoS ONE</i> , 2015, 10, e0117420.   | 1.1 | 54        |
| 63 | Phyto-liposomes as nanoshuttles for water-insoluble silybin-phospholipid complex. <i>International Journal of Pharmaceutics</i> , 2014, 471, 173-181.   | 2.6 | 50        |
| 64 | A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 989-993.  | 3.6 | 48        |
| 65 | BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 578, 395-405.   | 0.4 | 48        |
| 66 | Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 769-774.   | 1.9 | 46        |
| 67 | Clinical management of HCV carriers with normal aminotransferase levels. <i>Digestive and Liver Disease</i> , 2003, 35, 362-369.  | 0.4 | 45        |
| 68 | A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2005, 12, 292-299.                         | 1.0 | 45        |
| 69 | Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? [letter]. <i>Blood</i> , 1996, 88, 752-754.  | 0.6 | 43        |
| 70 | HCV genotypes in patients with liver disease of different stages and severity. <i>Journal of Hepatology</i> , 1997, 26, 1173-1178.  | 1.8 | 43        |
| 71 | Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon $\alpha$ -2b for chronic hepatitis type C. <i>Journal of Hepatology</i> , 1997, 27, 56-62.   | 1.8 | 42        |
| 72 | Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2447-2452.   | 1.1 | 41        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Chronic viral hepatitis: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S331-S343.  | 0.4 | 41        |
| 74 | Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.   | 1.9 | 41        |
| 75 | High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. <i>International Journal of Cancer</i> , 2011, 129, 536-545. | 2.3 | 40        |
| 76 | Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018, 38, 443-450.   | 1.9 | 40        |
| 77 | Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004, 40, 478-483.   | 1.8 | 38        |
| 78 | Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 424-431.      | 1.9 | 38        |
| 79 | Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017, 67, 680-686.  | 1.8 | 37        |
| 80 | Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. <i>Leukemia</i> , 1996, 10, 1209-13.  | 3.3 | 37        |
| 81 | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.  | 0.2 | 36        |
| 82 | IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014, 61, 235-241.  | 1.8 | 35        |
| 83 | External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 868-873.                                   | 0.2 | 34        |
| 84 | HLA and enteric antineuronal antibodies in patients with achalasia. <i>Neurogastroenterology and Motility</i> , 2006, 18, 520-525.  | 1.6 | 34        |
| 85 | Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 221-228.  | 1.8 | 34        |
| 86 | Tailoring the length of antiviral treatment for hepatitis C. <i>Gut</i> , 2010, 59, 1-5.  | 6.1 | 32        |
| 87 | Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.  | 0.6 | 32        |
| 88 | Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. <i>Pathologica</i> , 2021, 113, 170-184.   | 1.3 | 32        |
| 89 | HCV chronic infection and CCR5-Δ32/Δ32. <i>Gastroenterology</i> , 2003, 124, 868-869.   | 0.6 | 30        |
| 90 | The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. <i>Liver International</i> , 2016, 36, 971-976.   | 1.9 | 30        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 1994, 43, 125-128.                               | 2.5 | 29        |
| 92  | Short-term treatment duration for HCV-2 and HCV-3 infected patients. <i>Digestive and Liver Disease</i> , 2006, 38, 741-748.   | 0.4 | 29        |
| 93  | Hepatitis C virus chronic infection and oral lichen planus: an Italian case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 647-652.                               | 0.8 | 28        |
| 94  | Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. <i>Clinica Chimica Acta</i> , 2021, 522, 144-151.   | 0.5 | 28        |
| 95  | Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. <i>Journal of Hepatology</i> , 2001, 34, 441-446.         | 1.8 | 27        |
| 96  | Short-Term Therapy for Patients with Hepatitis C Virus Genotype 3 Infection. <i>Drugs</i> , 2006, 66, 1807-1815.   | 4.9 | 27        |
| 97  | Gene expression profile of Huh7 cells expressing hepatitis C virus genotype 1b or 3a core proteins. <i>Liver International</i> , 2009, 29, 661-669.  | 1.9 | 27        |
| 98  | Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.                  | 6.1 | 26        |
| 99  | Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. <i>Journal of Hepatology</i> , 2010, 53, 1000-1005.                         | 1.8 | 26        |
| 100 | Insulin resistance, steatosis and hepatitis C virus. <i>Hepatology International</i> , 2013, 7, 782-789.   | 1.9 | 26        |
| 101 | Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. <i>Digestive and Liver Disease</i> , 2014, 46, S179-S185.   | 0.4 | 26        |
| 102 | Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 770-780.                           | 0.5 | 26        |
| 103 | The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. <i>BioMed Research International</i> , 2015, 2015, 1-12.   | 0.9 | 25        |
| 104 | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. <i>PLoS ONE</i> , 2019, 14, e0215783.                  | 1.1 | 24        |
| 105 | Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients. <i>Journal of Virology</i> , 1999, 59, 277-280.  |     | 23        |
| 106 | Cytokine profile evaluation in patients with hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9261-9.   | 1.4 | 23        |
| 107 | Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. <i>Journal of Hepatology</i> , 2017, 66, 711-717.  | 1.8 | 22        |
| 108 | High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. <i>Journal of Hepatology</i> , 2002, 37, 109-116. | 1.8 | 21        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979. | 2.9  | 21        |
| 110 | The Cytokine Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0134594.   | 1.1  | 21        |
| 111 | Sofosbuvir and Velpatasvir for Patients with HCV Infection. <i>New England Journal of Medicine</i> , 2016, 374, 1687-1689.  | 13.9 | 20        |
| 112 | AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.   | 0.4  | 20        |
| 113 | Use of experimental design for optimisation of the cold plasma ICP-MS determination of lithium, aluminum and iron in soft drinks and alcoholic beverages. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 251-256.                 | 0.7  | 19        |
| 114 | Treatment of patients with HCV infection with or without liver biopsy. <i>Journal of Viral Hepatitis</i> , 2004, 11, 536-542.   | 1.0  | 19        |
| 115 | Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8924.  | 1.4  | 19        |
| 116 | IL28B Cc-Genotype Association with Hla-Dqb1*0301 Allele Increases the Prediction of Spontaneous HCV RNA Clearance in Thalassaemic HCV-Infected Patients. <i>Antiviral Therapy</i> , 2011, 16, 1309-1316.  | 0.6  | 18        |
| 117 | Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1966-1972.  | 0.2  | 17        |
| 118 | Thymosin alpha $\alpha$ 1 with peginterferon alfa $\alpha$ 2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 52-59.  | 1.0  | 17        |
| 119 | A <sc>STAT</sc>4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.   | 1.9  | 17        |
| 120 | SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. <i>Cells</i> , 2019, 8, 313.   | 1.8  | 17        |
| 121 | Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?. <i>World Journal of Clinical Cases</i> , 2020, 8, 5831-5834.   | 0.3  | 17        |
| 122 | To biopsy or not to biopsy. <i>Hepatology</i> , 2001, 34, 438-438.  | 3.6  | 16        |
| 123 | The use of molecular assays in the management of viral hepatitis. <i>Digestive and Liver Disease</i> , 2008, 40, 395-404.   | 0.4  | 16        |
| 124 | Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.   | 0.9  | 16        |
| 125 | Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg $\alpha$ 2 interferon and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1346-1353.  | 1.9  | 15        |
| 126 | Hepatitis C virus micro-elimination: Where do we stand?. <i>World Journal of Gastroenterology</i> , 2021, 27, 1728-1737.  | 1.4  | 15        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. <i>Digestive and Liver Disease</i> , 2002, 34, 285-289.  | 0.4 | 14        |
| 128 | What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140.   | 1.9 | 14        |
| 129 | Novel approach to separation and identification of organometallic compounds in complex mixtures by means of particle beam liquid chromatography/mass spectrometry: the case of diphosphine-substituted selenido iron and ruthenium clusters. , 1998, 12, 225-230. |     | 13        |
| 130 | Hepatitis C Infection in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2008, 31, 15-33.   | 0.7 | 13        |
| 131 | HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.                         | 1.3 | 13        |
| 132 | Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , 2018, 68, S67-S68.   | 1.8 | 12        |
| 133 | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 913.  | 2.1 | 12        |
| 134 | Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. <i>Frontiers in Public Health</i> , 2022, 10, 847384.                                     | 1.3 | 12        |
| 135 | Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. <i>Liver International</i> , 2011, 31, 36-41.   | 1.9 | 11        |
| 136 | IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naïve patients with chronic HCV genotype 1 infection: the international observational Gen-C study. <i>SpringerPlus</i> , 2016, 5, 1990.                                       | 1.2 | 11        |
| 137 | GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.                 | 1.8 | 11        |
| 138 | Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 2019-2026.   | 1.4 | 11        |
| 139 | Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 331-337.  | 1.9 | 10        |
| 140 | Progress in promising anti-fibrotic therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1145-1152.   | 1.4 | 10        |
| 141 | Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7144.                  | 1.2 | 10        |
| 142 | Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.   | 2.4 | 10        |
| 143 | Short-duration therapy for hepatitis C: suitable for all?. <i>Journal of Viral Hepatitis</i> , 2007, 14, 221-227.   | 1.0 | 9         |
| 144 | 5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION). <i>Journal of Hepatology</i> , 2013, 58, S3.               | 1.8 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | P1112 LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES. <i>Journal of Hepatology</i> , 2014, 60, S449.   | 1.8 | 9         |
| 146 | Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.  | 0.4 | 9         |
| 147 | Undetectable <sc>HCV</sc>â€<sc>RNA</sc> at treatmentâ€week 8 results in highâ€sustained virological response in <sc>HCV</sc> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> . 2015, 22, 469-480. | 1.0 | 9         |
| 148 | Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. <i>BMC Gastroenterology</i> , 2020, 20, 251.   | 0.8 | 9         |
| 149 | 1331 LACK OF ASSOCIATION BETWEEN IL28B VARIANTS AND HBSAG CLEARANCE AFTER INTERFERON TREATMENT. <i>Journal of Hepatology</i> , 2011, 54, S525.  | 1.8 | 8         |
| 150 | Treatment of Non-Genotype 1 Hepatitis C Virus Patients. <i>Current Gastroenterology Reports</i> , 2012, 14, 87-93.  | 1.1 | 8         |
| 151 | Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. <i>Digestive and Liver Disease</i> , 2013, 45, 356-361.   | 0.4 | 8         |
| 152 | Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras. <i>Journal of Hepatology</i> , 2016, 64, S136.  | 1.8 | 8         |
| 153 | TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017, 153, 1448-1449.  | 0.6 | 8         |
| 154 | Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 772-778.   | 1.0 | 8         |
| 155 | Associations between Allelic Variants of the Human IgH 3â€² Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2021, 9, 1207.  | 2.1 | 8         |
| 156 | Gallbladder Emptying in Patients with Primary Achalasia. <i>Digestion</i> , 1992, 52, 152-156.  | 1.2 | 7         |
| 157 | Development of a multigenic plasmid vector for HCV DNA immunization. <i>Research in Virology</i> , 1998, 149, 315-319.  | 0.7 | 7         |
| 158 | Clinical Significance of the CCR5delta32 Allele in Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e106424.   | 1.1 | 7         |
| 159 | Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S29.   | 1.8 | 7         |
| 160 | Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0200568.  | 1.1 | 7         |
| 161 | A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-Î²1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.  | 1.6 | 7         |
| 162 | Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patientâ€centered program from Italy. <i>United European Gastroenterology Journal</i> , 2021, 9, 1109.  | 1.6 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Sofosbuvirâ€velpatasvirâ€voxilaprevir in adolescents 12 to 17 years old with HCV infection. <i>Hepatology</i> , 2022, 76, 445-455.   | 3.6 | 7         |
| 164 | 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. <i>Journal of Hepatology</i> , 2004, 40, 34.  | 1.8 | 6         |
| 165 | Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. <i>Journal of Medical Economics</i> , 2008, 11, 151-163.  | 1.0 | 6         |
| 166 | Early discontinuation of ribavirin in HCVâ€2 and HCVâ€3 patients responding to Pegâ€interferon alphaâ€2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2009, 16, 28-35.   | 1.0 | 6         |
| 167 | IL28B: A new wager in the skyline of hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2011, 43, 177-179.  | 0.4 | 6         |
| 168 | Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017, 7, 15843.   | 1.6 | 6         |
| 169 | Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 190-200.   | 0.7 | 6         |
| 170 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1924-1928.  | 0.2 | 6         |
| 171 | Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343. | 0.4 | 6         |
| 172 | Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 <sup>21</sup> . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.  | 2.6 | 6         |
| 173 | Update on the Treatment of Patients With Nonâ€Genotype 1 Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1294-1300.   | 2.9 | 5         |
| 174 | Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.  | 1.1 | 5         |
| 175 | THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 70, e225.   | 1.8 | 5         |
| 176 | Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .   | 1.8 | 5         |
| 177 | A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.  | 1.9 | 5         |
| 178 | Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.  | 2.2 | 5         |
| 179 | High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55â€85. <i>Pathogens</i> , 2021, 10, 695.   | 1.2 | 5         |
| 180 | Individualized Treatment of Genotype 1 NaÃve Patients: An Italian Multicenter Field Practice Experience. <i>PLoS ONE</i> , 2014, 9, e110284.   | 1.1 | 5         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 181 | Peginterferon Alfa-2b and Ribavirin for 12 versus 24 Weeks in HCV Infection. <i>New England Journal of Medicine</i> , 2005, 353, 1182-1183.   | 13.9 | 4         |
| 182 | [7] IN PTS WHO CLEAR HCVRNA AT WEEK 12, SVR IS HIGHER AFTER 72 THAN AFTER 48 WEEKS TX: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (RCT). <i>Journal of Hepatology</i> , 2007, 46, S6.   | 1.8  | 4         |
| 183 | Short treatment to patients with genotype 2 or 3. <i>Hepatology</i> , 2008, 48, 694-694.  | 3.6  | 4         |
| 184 | Treating fatty liver for the prevention of cardiovascular diseases. <i>Hepatology</i> , 2010, 52, 1174-1175.  | 3.6  | 4         |
| 185 | 1170 IL28B C/C POLYMORPHISM IS PREDICTIVE OF SPONTANEOUS HCV RNA CLEARANCE IN PATIENTS WITH THALASSEMIA MAJOR. <i>Journal of Hepatology</i> , 2010, 52, S452.   | 1.8  | 4         |
| 186 | Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. <i>Liver International</i> , 2014, 34, e308-16.  | 1.9  | 4         |
| 187 | Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. <i>Liver International</i> , 2015, 35, 482-488.   | 1.9  | 4         |
| 188 | Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. <i>Hepatology</i> , 2016, 64, 2264-2265.   | 3.6  | 4         |
| 189 | Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. <i>Advances in Therapy</i> , 2021, 38, 1397-1403.   | 1.3  | 4         |
| 190 | Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. <i>BMC Infectious Diseases</i> , 2022, 22, 3.   | 1.3  | 4         |
| 191 | PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC). <i>Journal of Hepatology</i> , 2003, 38, 146.   | 1.8  | 3         |
| 192 | 8 FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION. <i>Journal of Hepatology</i> , 2008, 48, S6.   | 1.8  | 3         |
| 193 | 756 LARGE-SCALE MULTICENTER COMPARISON OF THREE ALGORITHMS COMBINING SERUM NON-INVASIVE MARKERS FOR LIVER FIBROSIS IN CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2008, 48, S282.   | 1.8  | 3         |
| 194 | O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY. <i>Journal of Hepatology</i> , 2014, 60, S523-S524. | 1.8  | 3         |
| 195 | Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.   | 1.1  | 3         |
| 196 | P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1 HCV infection. <i>Journal of Hepatology</i> , 2015, 62, S855-S856.  | 1.8  | 3         |
| 197 | The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.                              | 0.8  | 3         |
| 198 | Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multicentre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018, 25, 920-929.   | 1.0  | 3         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.  | 1.0  | 3         |
| 200 | Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. <i>Medicine (United States)</i> , 2018, 97, e11307.   | 0.4  | 3         |
| 201 | Thrombosis, recurrent abortions and intrauterine foetal death in a patient with lupus anticoagulant. <i>Clinical Rheumatology</i> , 1985, 4, 455-457.   | 1.0  | 2         |
| 202 | Skin is not a site of HCV replication in lichen planus (LP). <i>Gastroenterology</i> , 1998, 114, A1295.  | 0.6  | 2         |
| 203 | Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study. <i>Journal of Hepatology</i> , 2003, 38, 129. | 1.8  | 2         |
| 204 | 630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B. <i>Journal of Hepatology</i> , 2009, 50, S232.  | 1.8  | 2         |
| 205 | 126 PREDICTIVE ROLE OF IL28B C/C GENOTYPE ON SVR AND RVR IN PATIENTS WITH GENOTYPE 2/3 CHRONIC INFECTION. <i>Journal of Hepatology</i> , 2010, 52, S56-S57.   | 1.8  | 2         |
| 206 | High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV). <i>Journal of Hepatology</i> , 2018, 68, S273-S274.  | 1.8  | 2         |
| 207 | Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , 2013, 108, S123.   | 0.2  | 2         |
| 208 | Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHECY Cohort. <i>Hepato-Gastroenterology</i> , 2014, 61, 1094-106.  | 0.5  | 2         |
| 209 | Thromboxane production in diabetes mellitus. <i>Research in Clinic and Laboratory</i> , 1986, 16, 539-542.  | 0.3  | 2         |
| 210 | Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV. <i>New England Journal of Medicine</i> , 2007, 357, 1660-1662.   | 13.9 | 1         |
| 211 | Are HCV genotypes 2 and 3 the same or different?. <i>Current Hepatitis Reports</i> , 2008, 7, 88-92.  | 0.3  | 1         |
| 212 | Reply.. <i>Hepatology</i> , 2008, 48, 1020-1021.  | 3.6  | 1         |
| 213 | Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines. <i>Hepatology</i> , 2009, 50, 323-323.   | 3.6  | 1         |
| 214 | Optimal dosage of ribavirin. <i>Hepatology</i> , 2010, 52, 1173-1174.   | 3.6  | 1         |
| 215 | 851 GENETIC PREDICTORS OF STEATOSIS AND FIBROSIS IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Journal of Hepatology</i> , 2011, 54, S339-S340.  | 1.8  | 1         |
| 216 | 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHECY COHORT STUDY. <i>Journal of Hepatology</i> , 2012, 56, S32.  | 1.8  | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | 1135 IL28B CC GENOTYPE IS ASSOCIATED WITH HIGHER ON-TREATMENT-RESPONSE RATES IN PTS WITH HCV-3: INTERIM RESULTS OF THE WRITE STUDY. <i>Journal of Hepatology</i> , 2012, 56, S448.  | 1.8 | 1         |
| 218 | 1085 PEG-INTERFERON AND RIBAVIRIN IN HCV-RELATED CIRRHOTIC PATIENTS WITH PROFOUND THROMBOCYTOPENIA. <i>Journal of Hepatology</i> , 2012, 56, S426-S427.   | 1.8 | 1         |
| 219 | Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1259.  | 1.8 | 1         |
| 220 | 1171 EFFECTS OF A NEW LIPOSOME-ENCAPSULATED FORMULATION OF SILYBIN ON HEPATITIS C VIRUS INFECTION. <i>Journal of Hepatology</i> , 2013, 58, S476.   | 1.8 | 1         |
| 221 | In routine clinical practice, few physicians use early viral kinetics to guide <scp>HCV</scp> dual therapy treatment decisions. <i>Liver International</i> , 2014, 34, e217-28.   | 1.9 | 1         |
| 222 | 75. <i>Cytokine</i> , 2014, 70, 45-46.  | 1.4 | 1         |
| 223 | Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey. <i>Digestive and Liver Disease</i> , 2014, 46, e12.   | 0.4 | 1         |
| 224 | P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS. <i>Journal of Hepatology</i> , 2014, 60, S495. | 1.8 | 1         |
| 225 | Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience. <i>Journal of Hepatology</i> , 2016, 64, S246-S247.             | 1.8 | 1         |
| 226 | On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies. <i>Journal of Hepatology</i> , 2016, 64, S817.   | 1.8 | 1         |
| 227 | Mortality rate and predictors of liver disease damage in histologically diagnosed Nonalcoholic Steatohepatitis: a 15 years follow-up cohort study. <i>Journal of Hepatology</i> , 2017, 66, S148.   | 1.8 | 1         |
| 228 | Predictors of sustained virological response 12 weeks after the end of treatment in hepatitis C virus GT3 infected patients receiving IFN-free antiviral treatments. <i>Journal of Hepatology</i> , 2017, 66, S281.   | 1.8 | 1         |
| 229 | Dual proteotoxic stress accelerates liver injury via activation of <scp>p62</scp>. <i>Journal of Pathology</i> , 2021, 254, 80-91.  | 2.1 | 1         |
| 230 | Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings. <i>Future Virology</i> , 0, , .   | 0.9 | 1         |
| 231 | Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1096-1097.  | 1.9 | 1         |
| 232 | Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 7024-7033.  | 0.5 | 1         |
| 233 | Does genotype affect the course of HCV infection?. <i>Gastroenterology</i> , 1995, 108, A1117.  | 0.6 | 0         |
| 234 | Hepatitis B virus (HBV) reinfection in liver transplant patients receiving hepatitis B immune globulin: Role of S mutants. <i>Journal of Hepatology</i> , 2000, 32, 44.   | 1.8 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Re-treatment with interferon plus ribavirin of chronic hepatitis C nonresponders to interferon monotherapy: A meta-analysis of individual patient data. <i>Digestive and Liver Disease</i> , 2001, 33, A60.   | 0.4 | 0         |
| 236 | Monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy: multi-center evaluation of the INNO-LiPA HBV-DR. <i>Journal of Hepatology</i> , 2001, 34, 137.  | 1.8 | 0         |
| 237 | A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 117. | 1.8 | 0         |
| 238 | IL-10 ATA haplotype and 1st interon IFN-gamma polymorphisms are more frequent in pts with spontaneous HCV clearance. <i>Journal of Hepatology</i> , 2002, 36, 117.  | 1.8 | 0         |
| 239 | High SVR rate in HCV pts with normal or increased ALT: A controlled study with IFN alpha 2B and ribavirin. <i>Journal of Hepatology</i> , 2003, 38, 153.  | 1.8 | 0         |
| 240 | A controlled trial on treatment of patients with HCV infection and abnormal liver function tests with or without liver biopsy. <i>Journal of Hepatology</i> , 2003, 38, 124.  | 1.8 | 0         |
| 241 | Unusual sonographic appearance of a haemorrhagic biliary cyst. <i>European Journal of Radiology Extra</i> , 2005, 54, 103-105.  | 0.1 | 0         |
| 242 | [436] THE HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPES 3a AND 1b DOWN-REGULATES INSULIN RECEPTOR SUBSTRATE 1 VIA GENOTYPE-SPECIFIC MECHANISMS. <i>Journal of Hepatology</i> , 2007, 46, S166.  | 1.8 | 0         |
| 243 | 609 BASELINE CHARACTERISTICS AND WEEK-4 RESPONSE AMONG 1546 CHC PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 AND 4: INTERIM RESULTS OF THE PROPHEYS COHORT. <i>Journal of Hepatology</i> , 2009, 50, S224.   | 1.8 | 0         |
| 244 | 256 BASELINE CHARACTERISTICS AND ON-TREATMENT PREDICTORS OF RESPONSES FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS OF THE MULTINATIONAL PROPHEYS COHORTS. <i>Journal of Hepatology</i> , 2010, 52, S108.  | 1.8 | 0         |
| 245 | T-10 Effect of prevalence of fibrosis stages on the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): Results of a large-scale, international study. <i>Digestive and Liver Disease</i> , 2011, 43, S80.  | 0.4 | 0         |
| 246 | OC.10.5: THE EFFECT OF PREVALENCE OF LIVER FIBROSIS STAGES IN PERFORMANCE OF NONINVASIVE FIBROSIS BIOMARKERS IN CHRONIC LIVER DISEASES (CLDS): RESULTS OF AN INDEPENDENT, INTERNATIONAL STUDY. <i>Digestive and Liver Disease</i> , 2011, 43, S141.   | 0.4 | 0         |
| 247 | 1088 RATES AND PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE AND RELAPSE IN ITALIAN NAIVE MONO-INFECTED CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON ALFA/RIBAVIRIN: PROPHEYS 2 FINAL ANALYSIS. <i>Journal of Hepatology</i> , 2012, 56, S427-S428.   | 1.8 | 0         |
| 248 | 1134 PREMATURE TREATMENT DISCONTINUATION OF PEG-IFN $\alpha$ -2A/RBV DUE TO GOOD VIRAL RESPONSES AND INSUFFICIENT VIRAL RESPONSES AMONG HCV GENOTYPE 1, 2 AND 3 PATIENTS FROM PROPHEYS. <i>Journal of Hepatology</i> , 2012, 56, S447-S448.   | 1.8 | 0         |
| 249 | 815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON ALFA/RIBAVIRIN IN TREATMENT-NAIVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHEYS COHORTS. <i>Journal of Hepatology</i> , 2013, 58, S334.  | 1.8 | 0         |
| 250 | 790 HEPATITIS C TREATMENT OUTCOMES AND PREDICTORS OF RESPONSE IN TREATMENT-NAIVE PATIENTS TREATED WITH PEGINTERFERON ALFA/RIBAVIRIN IN REAL-WORLD ITALIAN CLINICS COMPARED WITH OTHER COUNTRIES: PROPHEYS SUB-ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S322.  | 1.8 | 0         |
| 251 | P1126 IMPACT OF SAFETY-RELATED DOSE REDUCTIONS AND DISCONTINUATIONS (SR-RD) ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA-2a/RIBAVIRIN: RESULTS FROM GUARD-C. <i>Journal of Hepatology</i> , 2014, 60, S455.   | 1.8 | 0         |
| 252 | Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors. <i>Digestive and Liver Disease</i> , 2014, 46, e45.   | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Reply to: "Built-in bias in HCV clearance in acute HCV infection". Journal of Hepatology, 2014, 60, 461-463.  | 1.8 | 0         |
| 254 | P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKER. Journal of Hepatology, 2014, 60, S490-S491.  | 1.8 | 0         |
| 255 | P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY. Journal of Hepatology, 2014, 60, S473.  | 1.8 | 0         |
| 256 | P.17.11 HIGH RATES OF VIROLOGICAL RESPONSES WITH PEG-IFN AND RBV RE-TREATMENT FOLLOWING RELAPSE TO SOF+RBV. Digestive and Liver Disease, 2014, 46, S124.  | 0.4 | 0         |
| 257 | P0858 : Early HCV RNA decline by baseline characteristics in HCV infected patients receiving sofosbuvir-based treatment: An Italian single center experience. Journal of Hepatology, 2015, 62, S662.  | 1.8 | 0         |
| 258 | 499 Ribavirin-Free Regimen With Velpatasvir and Sofosbuvir is Associated With High Efficiency and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From ASTRAL-2 and 3 Clinical Trials. Gastroenterology, 2016, 150, S1035. | 0.6 | 0         |
| 259 | 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin. Gastroenterology, 2016, 150, S1046.  | 0.6 | 0         |
| 260 | Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies. Gastroenterology, 2016, 150, S1092-S1093.     | 0.6 | 0         |
| 261 | Editorial: good news to patients with thalassaemia "HCV clearance made easy with direct acting antivirals. Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 629-630.   | 1.9 | 0         |
| 262 | Sustainable improvement of patient-reported outcomes in cirrhotic patients with hepatitis C who achieved sustained virologic response. Journal of Hepatology, 2018, 68, S530-S531.  | 1.8 | 0         |
| 263 | The evolution of treatment for HCV Genotype 3 (GT3) infected patients with advanced fibrosis/cirrhosis over time. Journal of Hepatology, 2018, 68, S274.  | 1.8 | 0         |
| 264 | THU-348-Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life. Journal of Hepatology, 2019, 70, e313.  | 1.8 | 0         |
| 265 | Current Management of Patients with HCV Genotype 2. , 2021, , 83-95.  |     | 0         |